Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, explains the background and results of the TOPAZ-1 study.
Sunil Verma, MD, senior vice president and global head of oncology, medical at AstraZeneca, explains the background and results of the TOPAZ-1 study, which evaluated the use of immunotherapy to improve overall survival and progression-free survival of biliary tract cancer. Results were presented at the recent American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
Transcript:
Can you discuss the purpose and results of the TOPAZ-1 study?
Let me start off by discussing biliary tract cancer. As you mentioned, hepatocellular cancer is also associated with delayed diagnosis and, similarly, with biliary tract cancer. These have very nonspecific symptoms where patients have some right upper abdominal pain, they may have some nausea, they may have some referred pain, and things that most people would suggest are nonspecific symptoms. Many of these patients are associated with very delayed diagnosis and, in biliary tract cancer, we have really not seen any major significant advances in this field for more than a decade, and the current main chemotherapy remains chemotherapy, and in most cases it is cisplatin- and gemcitabine-based chemotherapy. The trial TOPAZ-1 was looking to see, can we advance these outcomes for these patients with the use of immunotherapy? Patients were randomized to receiving cisplatin and gemcitabine, or cisplatin and gemcitabine plus durvalumab. Cisplatin and gemcitabine was given for a period of time, as is consistent traditional practice, and the durvalumab was continued until disease progression. The results, as shared at the ASCO GI meeting, suggest that there is a meaningful benefit in overall survival. I think that really is great news for patients and their families with this disease.
Transcript edited for clarity.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More